Rodrigues E, Giovanini A, Ribas C, Malafaia O, Roesler R, Isolan G
Cancers (Basel). 2023; 15(20).
PMID: 37894289
PMC: 10605093.
DOI: 10.3390/cancers15204922.
Dai L, Shen K, Zhang C
Histol Histopathol. 2023; 38(11):1239-1248.
PMID: 37170703
DOI: 10.14670/HH-18-625.
Szczerba K, Stokowa-Soltys K
Pharmaceuticals (Basel). 2023; 16(3).
PMID: 36986466
PMC: 10058266.
DOI: 10.3390/ph16030366.
Keough M, Monje M
Annu Rev Neurosci. 2022; 45:199-221.
PMID: 35259916
PMC: 10234771.
DOI: 10.1146/annurev-neuro-111020-092702.
van Kessel E, Berendsen S, Baumfalk A, Venugopal H, Krijnen E, Spliet W
Neuro Oncol. 2022; 24(10):1660-1670.
PMID: 35148403
PMC: 9527514.
DOI: 10.1093/neuonc/noac036.
The Role of Neuropilin-2 in the Epithelial to Mesenchymal Transition of Colorectal Cancer: A Systematic Review.
Lungulescu C, Ghimpau V, Gheonea D, Sur D, Lungulescu C
Biomedicines. 2022; 10(1).
PMID: 35052853
PMC: 8773800.
DOI: 10.3390/biomedicines10010172.
Inhibition of Sema-3A Promotes Cell Migration, Axonal Growth, and Retinal Ganglion Cell Survival.
Nitzan A, Corredor-Sanchez M, Galron R, Nahary L, Safrin M, Bruzel M
Transl Vis Sci Technol. 2021; 10(10):16.
PMID: 34817617
PMC: 8626852.
DOI: 10.1167/tvst.10.10.16.
Re-Expression of Poly/Oligo-Sialylated Adhesion Molecules on the Surface of Tumor Cells Disrupts Their Interaction with Immune-Effector Cells and Contributes to Pathophysiological Immune Escape.
Jarahian M, Marofi F, Maashi M, Ghaebi M, Khezri A, Berger M
Cancers (Basel). 2021; 13(20).
PMID: 34680351
PMC: 8534074.
DOI: 10.3390/cancers13205203.
Multifaceted Functional Role of Semaphorins in Glioblastoma.
Angelucci C, Lama G, Sica G
Int J Mol Sci. 2019; 20(9).
PMID: 31052281
PMC: 6539029.
DOI: 10.3390/ijms20092144.
Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers.
Hui D, Tam K, Jiao I, Ong C
Int J Mol Sci. 2019; 20(3).
PMID: 30759745
PMC: 6386986.
DOI: 10.3390/ijms20030774.
Emerging role of semaphorin-3A in autoimmune diseases.
Liu L, Li X, Ye D, Pan H
Inflammopharmacology. 2018; 26(3):655-665.
PMID: 29696565
DOI: 10.1007/s10787-018-0484-y.
Semaphorin 3C and Its Receptors in Cancer and Cancer Stem-Like Cells.
Hao J, Yu J
Biomedicines. 2018; 6(2).
PMID: 29642487
PMC: 6027460.
DOI: 10.3390/biomedicines6020042.
Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo.
Wonder E, Simon-Gracia L, Scodeller P, Majzoub R, Kotamraju V, Ewert K
Biomaterials. 2018; 166:52-63.
PMID: 29544111
PMC: 5944340.
DOI: 10.1016/j.biomaterials.2018.02.052.
Silencing of semaphorin 3C suppresses cell proliferation and migration in MCF-7 breast cancer cells.
Zhu X, Zhang X, Ye Z, Chen Y, Lv L, Zhang X
Oncol Lett. 2017; 14(5):5913-5917.
PMID: 29113226
PMC: 5661468.
DOI: 10.3892/ol.2017.6920.
Semaphorin 3 C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cells.
Tam K, Hui D, Lee W, Dong M, Tombe T, Jiao I
Sci Rep. 2017; 7(1):11501.
PMID: 28904399
PMC: 5597577.
DOI: 10.1038/s41598-017-11914-6.
Neural Precursor-Derived Pleiotrophin Mediates Subventricular Zone Invasion by Glioma.
Qin E, Cooper D, Abbott K, Lennon J, Nagaraja S, Mackay A
Cell. 2017; 170(5):845-859.e19.
PMID: 28823557
PMC: 5587159.
DOI: 10.1016/j.cell.2017.07.016.
iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
Simon-Gracia L, Hunt H, Scodeller P, Gaitzsch J, Kotamraju V, Sugahara K
Biomaterials. 2016; 104:247-57.
PMID: 27472162
PMC: 5687559.
DOI: 10.1016/j.biomaterials.2016.07.023.
Semaphorin-3C signals through Neuropilin-1 and PlexinD1 receptors to inhibit pathological angiogenesis.
Yang W, Hu J, Uemura A, Tetzlaff F, Augustin H, Fischer A
EMBO Mol Med. 2015; 7(10):1267-84.
PMID: 26194913
PMC: 4604683.
DOI: 10.15252/emmm.201404922.
High level of Sema3C is associated with glioma malignancy.
Vaitkiene P, Skiriute D, Steponaitis G, Skauminas K, Tamasauskas A, Kazlauskas A
Diagn Pathol. 2015; 10:58.
PMID: 26032848
PMC: 4450827.
DOI: 10.1186/s13000-015-0298-9.
Plexin-B2 promotes invasive growth of malignant glioma.
Le A, Huang Y, Pingle S, Kesari S, Wang H, Yong R
Oncotarget. 2015; 6(9):7293-304.
PMID: 25762646
PMC: 4466685.
DOI: 10.18632/oncotarget.3421.